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approach using embedded materials
with well-defined elastic moduli,
and at controlled depths within a
phantom matrix, must also be under-
taken. Furthermore, the experimental
measurements must be used to validate
computational models of these same
scenarios, as in the study conducted
by Roduit et al. (2009). When such
data are forthcoming and a platform of
confidence in the approach has been
firmly established, then the pursuit of
more intricate relationships, such
as the depth dependence of filaggrin
degradation suggested by Beard et al.
(2013), ought to be possible. By
undertaking parallel electrophysiology
on targeted structures during the nano-
indentation process, perhaps by the
implementation of recent microfabri-
cation innovations for intra-cellular
recording (Duan et al., 2011), a real-
time assessment of membrane trafficking
can also be undertaken during the critical
bulk penetration stage, which will
inform on downstream viability profiles.
The emergence of the new tomo-
graphy technique is also rather timely:
researchers will not have to go through
the trouble and expense involved in
generating their own ‘nano-needle’ tips,
as commercially available entities have
already emerged (viz NaugaNeedles.com
or www.Nanotools.com for example). It
would thus seem that the only short-term
limitation with local probe tomography
will rest in the collective imagination of
its first wave of users.
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Circulating Melanoma Cells as a
Predictive Biomarker
Giorgos Karakousis1, Ruifeng Yang2 and Xiaowei Xu2
The prognosis of patients with metastatic melanoma has improved significantly
with targeted therapeutic agents and immunotherapies. Detection of early
melanoma recurrence after treatment will be beneficial to switch patients who
fail on one therapy to different modalities. Circulating tumor cells (CTCs) are
cancer cells released by a tumor into the peripheral blood. These cells hold
potential as prognostic, predictive, and pharmacodynamic biomarkers for treat-
ment. In this issue, Khoja et al. report that melanoma CTCs can be detected using
Melcam and high molecular weight melanoma–associated antibody. They found
that in 101 stage IV melanoma patients, CTC numbers ranged between 0 and 36/
7.5ml blood; 26% of the patients hadX2 CTCs at baseline. The CTC number (X2
CTCs) at baseline was significantly prognostic for median overall survival (OS) in
univariate and multivariate analysis. Patients receiving treatment where CTC
numbers remained X2 CTCs during their treatment had shorter median OS than
those who maintained o2 CTCs (7 vs. 10 months, hazard ratio 0.34, 95%
confidence interval 0.14–0.81, log-rank test P¼ 0.015). The implications of this
work are substantial in counseling patients about their prognosis and in helping to
assess responses to systemic therapies.
Journal of Investigative Dermatology (2013) 133, 1460–1462. doi:10.1038/jid.2013.34
Targeted therapies such as the mutant
BRAF selective inhibitors vemurafenib
and dabrafenib have improved the sur-
vival of patients with metastatic mela-
noma (Flaherty et al., 2010, 2012a,b;
Sosman et al., 2012). However,
subsequent drug resistance and disease
progression has been observed in most
of the treated patients (Flaherty, 2012).
Anti-CTLA4 and anti-PD1 immuno-
therapies have also improved overall
survival (OS) in metastatic melanoma
patients, with a subset of patients having
long-term survival (Hodi et al., 2010;
Lipson et al., 2013). With effective
therapies of this sort, it has become
important to monitor patients and to
identify early signs of treatment failure.
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However, detection of early recurrence
and treatment failure is difficult, and
obtaining tumor biopsies is not without
risk. Less invasive approaches to assess
treatment responses would therefore
have clinical utility.
During tumor progression, a sub-
population of tumor cells gain access
and escape into the lymphatic or blood
vessels and circulate until they are either
eliminated by host response mechan-
isms or find an microenvironment in
which to reside where they may
eventually proliferate. In our own work,
we found that lymphatic invasion
occurs commonly in primary melano-
mas (Xu et al., 2008, 2012). Importantly,
the detection of circulating tumor
cells (CTCs) in the peripheral blood of
patients with cancer has prognostic and
therapeutic implications (Cristofanilli
et al., 2004). However, the number of
CTCs can be very small, and these cells
are not easily detected. Therefore, a key
to the use of CTCs as a biomarker is
technology designed to enrich cancer
cells from peripheral blood. FDA
has approved the Veridex CellTrack
Analyzer for use in monitoring
therapeutic responses in patients with
breast, prostate, or colon cancer. This
technology relies on the expression of
epithelial cellular adhesion molecular
(EpCAM). Most CTC studies in the
literature have focused on epithelial
cancers.
In the study reported by Khoja et al.
(2013), the authors used a melanoma-
specific CellSearch CTC kit, using
Melcam and high molecular weight
melanoma associated antibody (HMW-
MAA), which is also identified as a
melanoma-associated chondroitin sul-
fate proteoglycan antibody for melanoma
CTC capture and detection. Both
markers are reported to be expressed
in up to 80% of metastatic melanoma
lesions (Campoli et al., 2004). The
authors found that 40% of melanoma
patients in a cohort of 101 have one or
more CTCs at baseline, with nearly
79% having advanced M1c disease. In
patientso60 years of age, the sensitivity
of CTCs above 0 was 33%. Using the
threshold of X2 CTCs, which the
authors proposed as useful, 26% of the
patients fell into this category.
Multivariate Cox proportional hazards
regression analysis demonstrated that,
after adjusting for other significant
univariate factors, such as lactate
dehydrogenase, performance status,
treatment with a BRAF or MEK
inhibitor, CTC number was an
independent prognostic factor for OS
(hazard ratio (HR) 2.403, 95%
confidence interval (CI) 1.303–4.430,
P¼0.005). Although melanoma CTCs
identified by Melcam and HMW-MAA
indeed did identify a cohort of patients
with extremely poor prognosis, the
remaining cohort (74%) still had a
relatively poor outcome with a median
OS of only 7.2 months. Thus, it is
conceivable that a majority of stage
M1c melanoma patients have CTCs in
their peripheral blood; however, these
CTCs are not detectable by the
combination of Melcam and HMW-
MAA antibodies. As pointed out by the
authors, the level of antigen expression
on melanoma cells in the circulation is
unknown, especially with respect to the
detection limits of the Veridex platform.
CTCs may therefore have different
surface antigen characteristics than do
the corresponding tissue metastases.
Low melanocytic marker expression on
CTCs may be one of the reasons why
the majority of their patients (75%) had
o2 CTCs and 60% had no CTCs.
Therefore, other melanocytic markers
should be tested to optimize detection
of melanoma CTCs.
The authors also explored the phar-
macodynamic CTC changes and prog-
nostic significance of CTC number after
treatment. Although the sample size is
relatively small (28 of 45 patients exhib-
ited pharmacodynamic changes in CTC
number), the prognostic significance of
CTC number recorded before and at any
time point during treatment for all 45
patients confirmed longer survival for
patients witho2 CTCs at any time point
during treatment (10 vs. 7 months, HR
0.34, CI 0.14–0.81, log-rank test
P¼0.015). As CTCs were measured at
6–9 weeks post initiation of treatment in
the current study, it would be interesting
to measure the CTC number at very
early time points after initiation of ther-
apy, to see if clinical responses could be
predicted prior to their occurrence.
Nevertheless, the implications of this
work are significant both for counseling
patients on prognosis and also for help-
ing to assess the response to systemic
therapies.
Despite the progress of research on
CTCs, the biology of CTCs needs to be
further characterized. It is still unclear
whether CTCs are similar to the bulk of
tumor cells in the primary site or to solid
metastases, whether they represent the
so-called ‘‘tumor-initiating cells’’, and
whether there is heterogeneity among
CTCs in an individual patient on the
molecular level. More studies are
needed to address these important
issues.
Summary
The work by Khoja et al. (2013) imparts
important insights into the melanoma
biology. The investigators provide
evidence that melanoma CTCs can be
detected using antibodies against
melanocyte surface markers. CTC
number (X2 CTCs) is an independent
worse prognostic biomarker of OS.
Patients receiving treatment where CTC
number remained at X2 CTCs during
treatment had a shorter median OS
than those that maintained o2 CTCs.
Their work generates further impetus
for studies aimed at increasing the
sensitivity of melanoma CTC detection
Clinical Implications
 Melanoma circulating tumor cells (CTCs) can be detected using antibodies
against melanocyte surface markers.
 In multivariate analysis CTC number (X2 CTCs) is an independent
prognostic biomarker of overall survival (OS).
 Patients receiving treatment where CTC number remainedX2 CTCs during
treatment had shorter median OS than those who maintained o2 CTCs.
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and at addressing whether melanoma
CTCs can help serve as predictive
biomarkers for risk stratification of
patients for clinical treatments and for
early prediction of response to therapies.
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The Dark Side of Cyclophosphamide:
Cyclophosphamide-Mediated Ablation
of Regulatory T Cells
Ju¨rgen C. Becker1 and David Schrama1
Cancer immune escape is frequently associated with the induction of an
inappropriate immune response, i.e., a response that does not inhibit but perhaps
even promotes the tumor. Indeed, increased frequencies of tumor-infiltrating
regulatory T cells (Tregs) are associated with an impaired prognosis in several
cancers. Thus, depletion of Tregs, e.g., by cyclophosphamide, was proposed as a
means to boost immune responses to cancer. In the present issue of the Journal,
Sevko et al., however, provide evidence that cyclophosphamide exerted the
unexpected effect of induction of myeloid-derived suppressor cells.
Journal of Investigative Dermatology (2013) 133, 1462–1465. doi:10.1038/jid.2013.67
Malignant cells can be detected and
destroyed by cells of the immune system
in general, and by cells of the adaptive
immune system in particular. In fact,
there is strong evidence that immunolo-
gical recognition has an impact on
prognosis (Mellman et al., 2011; Wang
et al., 2012). Nevertheless, there is
equally strong evidence that in many
cancer patients the cancerous cells
impair beneficial immune responses
(Kerkar and Restifo, 2012). Many of
the immune escape mechanisms are
based on the induction of what
we presume is an inappropriate immune
response, i.e., a response that does not
inhibit but perhaps even promotes the
tumor (Grivennikov et al., 2010).
Indeed, virtually all solid tumors
contain infiltrates of diverse leukocyte
subsets including both myeloid- and
lymphoid-lineage cells, whose profile
and activation status vary depending
on the tissue/organ milieu as well as
stage of malignancy. Notably, in some
tumors these inflammatory infiltrates are
similar in their effect to the resolution
phase of wound healing, i.e., they
contain immune-competent cells that
convey immunosuppressive activity
(Hanahan and Coussens, 2012). These
congregations include regulatory T cells
(Tregs), myeloid-derived suppressor
cells (MDSCs), type 2 tumor-associated
macrophages, neutrophils, and mast cell
subtypes; these cells may collectively or
alone enable cancer cells to escape
killing by cytotoxic cells (Sakaguchi
et al., 2008; Qian and Pollard, 2010;
Kodumudi et al., 2012) (Figure 1). Thus,
ablation or reprogramming of this aber-
rant microenvironment might dramati-
cally augment cancer therapies, and this
strategy is currently being deployed in a
variety of clinical trials (Mellman et al.,
2011; Wang et al., 2012).
Since the rediscovery of suppressor
T cells as CD4þCD25þ regulatory
T cells, this cell subset has become an
intense focus of cancer research
(Sakaguchi et al., 2008). Tregs can
develop in the thymus or can be
converted in the periphery by, for
example, exposure to transforming
growth factor (TGF)-b. Both ‘natural’
and ‘inducible’ Tregs utilize similar
mechanisms to mediate immune
suppression: (i) secretion of immune-
suppressive cytokines, e.g., TGF-b,
IL-35, and IL-10; (ii) direct killing
of effector T cells; (iii) metabolic
commotion, e.g., IL-2 deprivation; and
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